Regulatory & Reimbursement
Last reviewed 4 September 2026 · Trust Center / change history
Claim, evidence and market access have to move together.
The pathway is designed as a staged value-creation sequence: first establish performance and safety, then expand claims as clinical evidence supports them. Classification, conformity-assessment route and clinical requirements will be confirmed through formal review with qualified counsel and a Notified Body.
Regulatory hypothesis
MDR class IIb is the working route to confirm.
The planning assumption for Europe is class IIb. What matters more than the class is the honest cost structure behind it: the dominant driver is our own people, not the fees.
TÜV Rheinland price list v3.0, 27 October 2025 (application fee € 2,480; annual certificate maintenance € 2,410–15,000) · MedTech Europe Survey 2024, n = 211 · Team-NB Survey 2025: of new MDR certificates, 48 % take 13–18 months, 22 % take longer than 18 months and only 14 % are finished inside six months — 41 of the 52 designated notified bodies responded, covering 25,978 MDR certificates.
Annex VIII, drawn
Three rules point the same way — and one we design around.
The reading below is ours. We publish it so a Notified Body, an investor or a competitor can challenge it on the record rather than in a data room.
Swipe sideways to see the full path →
Classification
The rules the class actually comes from.
„Class IIb“ is not an opinion, it is the output of named rules in Annex VIII of the MDR. Here are the rules we read ourselves against, quoted, and what each one does to this device. The reading is ours and is not yet confirmed by a Notified Body.
Energy delivered to the body
„All active therapeutic devices intended to administer or exchange energy are classified as class IIa unless their characteristics are such that they may administer energy to or exchange energy with the human body in a potentially hazardous way, taking account of the nature, the density and site of application of the energy, in which case they are classified as class IIb.“Regulation (EU) 2017/745, Annex VIII, Chapter III
AIRCHILL exchanges thermal energy with the body through the lower airway. The site of application is the lung; the exchange is intended and continuous. We therefore read Rule 9 as landing on class IIb, which is also where the guidance already puts lung ventilators.
Substances administered to the body
„All active devices intended to administer and/or remove medicinal products, body liquids or other substances to or from the body are classified as class IIa, unless this is done in a manner that is potentially hazardous, taking account of the nature of the substances involved, of the part of the body concerned and of the mode of application in which case they are classified as class IIb.“Regulation (EU) 2017/745, Annex VIII, Chapter III
The device administers a cold, oxygen-carrying gas into the lower airway of an unconscious patient. Nature of the substance, part of the body and mode of application all argue for the hazardous branch, so this rule points to class IIb as well. Rule 12 of the MDR is the rule numbered 11 in the former Directive 93/42/EEC — older documents cite it that way.
The software inside it
„Software intended to monitor physiological processes is classified as class IIa, except if it is intended for monitoring of vital physiological parameters where the nature of variations of those parameters is such that it could result in immediate danger to the patient, in which case it is classified as class IIb.“Regulation (EU) 2017/745, Annex VIII, Chapter III
Control software that holds temperature, flow, FiO₂ and pressure on a ventilated patient monitors parameters whose variation is immediately dangerous. Software is planned as part of the device, not as a separate product — but it carries its own IEC 62304 obligations regardless of how it is classified.
The rule that could move us to class III
„Active therapeutic devices with an integrated or incorporated diagnostic function which significantly determines the patient management by the device, such as closed loop systems or automated external defibrillators, are classified as class III.“Regulation (EU) 2017/745, Annex VIII, Chapter III
This is the risk in the classification, and it is ours to manage: a device that measures a patient temperature and then automatically steers the therapy from it is a closed-loop system, and closed-loop systems are class III. The minimum certifiable configuration (MCC) is therefore specified as operator-set and open-loop. Automatic patient-temperature feedback is a later, separate regulatory decision with its own evidence and budget — not a function quietly carried into the first submission.
The FDA product classification database holds two categories that could receive this device, both class II and both 510(k): 21 CFR 868.5895, continuous ventilator, product code CBK — and 21 CFR 868.5925, powered emergency ventilator, product code BTL, whose recognised consensus standards already include ISO 10651-5 for gas-powered emergency resuscitators and the ISO 18562 breathing-gas-pathway series. Which of the two applies follows from the intended purpose, and neither of them covers controlled cooling, for which we have found no predicate. The US gates are set out further down this page.
Rule text quoted from Regulation (EU) 2017/745, Annex VIII, Chapter III · Annex VIII, consolidated text · classification examples from MDCG 2021-24, Guidance on classification of medical devices, which lists lung ventilators as class IIb under Rule 9 · 21 CFR 868.5925, powered emergency ventilator · FDA product classification database, product code BTL. This reading is our own preliminary analysis. Classification is confirmed by the Notified Body against the final intended purpose, and the intended purpose is not frozen.
Global approval paths
Europe, the United States and China require different first gates.
AIRCHILL is still a development-stage device. The routes below are regulatory planning hypotheses, not approvals or final classifications. The novel combination of ventilation and controlled respiratory cooling must be discussed with each authority before the market-access route is locked.
Class II / 510(k) is the starting hypothesis — not the conclusion.
FDA currently classifies continuous facility-use ventilators under 21 CFR 868.5895 as Class II, with 510(k) pathways such as product code CBK. AIRCHILL’s active cooling function may create different questions on intended use, technological characteristics and predicate suitability, so the first formal step should be a Q-Submission / Pre-Submission with CDRH.
Pre-Sub & classification strategy
Confirm intended use, likely product code, predicate strategy, non-clinical package and whether the cooling function still fits a 510(k) substantial-equivalence argument.
Bench, safety & usability
Build the evidence package around ventilator performance, electrical safety / EMC, EMS transport conditions, breathing-gas-path biocompatibility, software / cybersecurity where applicable, risk management and human factors.
Clinical study decision
Use the FDA interaction to determine whether a U.S. clinical investigation is significant risk and whether an IDE is required. Clinical evidence must follow the final claim; neurological benefit is not assumed.
510(k) or De Novo
If a legally marketed predicate supports substantial equivalence, pursue 510(k). If the integrated cooling function creates a new device type without an adequate predicate, De Novo is the planning fallback. PMA is not the base case.
FDA sources: 21 CFR 868.5895 / FDA Product Classification database; FDA Q-Submission Program; FDA IDE process; FDA-recognized ISO 80601-2-84 for EMS ventilators, IEC 60601-1-12 for the EMS environment and ISO 18562 for breathing-gas pathways. Since 2 February 2026, FDA’s QMSR incorporates ISO 13485:2016.
Imported Class III is the conservative planning case — formal classification comes first.
China’s device catalogue places life-support ventilator systems in the respiratory-device family 08-01 and classification results show Class III treatment ventilator systems. Because AIRCHILL adds a novel controlled-cooling function, we do not treat that catalogue fit as automatic: a formal classification determination should precede the registration plan.
Classification determination
Confirm whether AIRCHILL is registered as a Class III ventilator system, whether the cooling function changes the classification logic, and whether an innovative-device route is appropriate.
China technical package
Prepare Chinese product technical requirements, representative product testing, risk-management and quality-system documentation, plus the applicable respiratory / transport-ventilator standards and evidence for the cooled breathing-gas pathway.
Clinical evaluation
NMPA requires clinical evaluation unless an exemption applies. Existing literature and predicate-device data may support the evaluation; where they are insufficient, a clinical trial is required. Certain high-risk Class III trials require NMPA approval.
Imported-device registration
An overseas applicant designates a legal entity in China to submit the application. A home-country marketing certificate is generally part of an imported Class II / III filing; an unmarketed innovative medical device may qualify for the statutory exception. Eligibility has to be confirmed before relying on it.
China sources: NMPA Provisions for Medical Device Registration and Filing; NMPA import Class III registration service; NMPA medical-device classification rules; NIFDC medical-device classification catalogue / published classification results; NMPA innovative-device special review procedure.
The core engineering package should be reusable across MDR, FDA and NMPA: risk management, design controls, ventilator performance, airway safety, electrical safety / EMC, software where applicable, usability and manufacturing controls. What changes by market is the classification logic, submission format, clinical-evidence threshold and the claims that can be supported.
Accelerated routes
The same gap that makes a 510(k) hard is what makes Breakthrough available.
Both regulators run a route for devices that address a life-threatening or irreversibly debilitating condition where the existing alternatives are absent or insufficient. Neither route is an approval. Both can be requested years before a marketing submission, both work to a sixty-day target — and for a project at TRL 4 that makes them the earliest hard external checkpoint available anywhere in this plan.
Swipe sideways to see all four criteria →
Open to 510(k), De Novo and PMA alike — which is why it does not depend on the predicate question being settled first.
Criterion 1 is met on its face: cardiac arrest, stroke and traumatic brain injury are life-threatening and irreversibly debilitating. For criterion 2 we would argue that no approved or cleared alternative exists — neither 21 CFR 868.5895 (product code CBK) nor 868.5925 (BTL) covers controlled cooling, and our search found no predicate for that function. A request may be filed at any time before the marketing submission; FDA intends to request anything missing within thirty days and to communicate its decision within sixty calendar days. A designation brings sprint meetings, an agreed data development plan, a clinical protocol agreement and priority review.
One thing has to be checked before filing. Whether any device that cools through the airway has ever been cleared in the United States. RhinoChill has carried a CE mark since 2011; its FDA status is not something we have established. If a US clearance exists, the “no alternatives” argument falls and the case moves to criterion 1 or 3 — which is why we would rather know that now than after a submission is written.
Guidance on law already in force, endorsed December 2025 — not a legislative proposal.
MDCG 2025-9 describes how existing MDR instruments are used for breakthrough devices. Two criteria: a high degree of novelty in the device technology, the related clinical procedure or its application in clinical practice; and a significant positive clinical impact in a life-threatening or irreversibly debilitating condition — either as a clinically meaningful improvement over alternatives, or by meeting an unmet need where alternatives are absent or insufficient. The guidance states it may apply across all technologies and risk classifications.
For a class IIb device that does not administer a medicinal product, the route runs through Article 106(11) rather than the Article 61(2) advice reserved for class III and certain class IIb active devices. An opinion can be requested at any point in development where the data support the criteria; the expert panel is to endeavour to give its opinion within sixty days and to prioritise BtX requests. What follows is prioritised notified-body planning, early structured dialogue, and certificates carrying defined post-market clinical follow-up conditions.
A designation is not a clearance. An expert-panel opinion is not a certificate and not a commitment by a notified body. Neither reduces the evidence we have to generate: the bench work, the airway-safety package and the clinical study stay exactly as large as they were. Reimbursement is a separate question again — the Medicare route TCET is open to FDA-designated Breakthrough Devices, and CMS anticipates accepting up to five candidates a year. What the two routes do offer is the one thing a development-stage device normally cannot buy: a documented regulator’s view on the novelty argument, years before the submission that would otherwise be the first place to find out. If it is granted, it is a credential for investors and grant applications. If it is refused, we learn which criterion to build the case on — while the design is still open enough to build for it.
Sources, all checked 17 August 2026: FDA, Breakthrough Devices Program; MDCG 2025-9, Guidance on Breakthrough Devices (BtX), December 2025; CMS, final notice on Transitional Coverage for Emerging Technologies (CMS-3421-FN). The MDCG guidance states of itself that it is not legally binding.
Timeline & cost model
Three markets, one evidence core — but different clocks and budgets.
The ranges below are management planning envelopes, not authority quotations and not approval promises. They assume a frozen minimum certifiable configuration (MCC) built around the complete safety-critical ventilation/cooling core and, where regulatory impact remains proportionate, mature monitoring, suction, ECG/defibrillation or telemedicine hardware sourced as purchased or OEM subsystems. The strategy is not to save regulatory effort by building an artificially incomplete device: the main scope lever is a focused first intended purpose and claim set. Purchased hardware avoids re-developing mature subsystems, but it does not remove supplier controls, interface engineering, risk management or verification of the integrated AIRCHILL system. Functions that materially change classification or evidence requirements remain explicit gates. Clinical-outcome claims would require a separate and substantially larger programme.
~30–48 months from design freeze
Gate 0 · 3–6 months: intended purpose, MDR classification, Notified-Body strategy, oxygen/LOX boundary analysis. Planning spend: €75k–€250k external plus internal team.
Gate 1 · 9–18 months: QMS, design controls, risk management, prototype freeze and standards test programme. External laboratories, regulatory support and verification planning: €0.4m–€1.2m.
Gate 2 · 12–24 months: preclinical package and first clinical feasibility where required. Planning range: €1.5m–€4m, highly study-dependent.
Gate 3 · 18–24 months from formal application: IIb conformity assessment planning horizon including manufacturer response cycles. Notified-Body and specialist external spend is modelled at roughly €0.15m–€0.6m, excluding internal personnel and clinical work.
Company-level envelope: the existing management model remains €12m / €17m / €24m low/base/high to a performance claim. Regulatory fees are only a small part of that total.
~24–42 months for a 510(k) case; ~30–48 months for De Novo
Gate 0 · ~2–3 months: Q-Submission / Pre-Submission. FDA normally targets written feedback at about day 70; there is no FDA user fee for a Pre-Sub. External preparation budget: €50k–€150k.
Gate 1 · 9–18 months: FDA-recognized standards, bench, transport, gas-path, software, cybersecurity and human-factors verification. Planning range: €0.4m–€1.5m external.
Gate 2 · 0–24 months: clinical evidence only to the extent requested by FDA and required by the claim. If a Significant-Risk investigation is needed, IDE review has a 30-day statutory clock; study execution dominates time and cost. Planning range: €1.5m–€5m for a focused feasibility programme.
Gate 3: FDA review goal 90 FDA days for 510(k) or 150 FDA days for De Novo, excluding applicant hold time. FY2026 user fees are $26,067 / $6,517 small-business for 510(k) and $173,782 / $43,446 for De Novo; annual establishment registration is $11,423.
~24–48 months for the conservative imported-Class-III case
Gate 0 · ~1–3 months practical: classification determination and, if oxygen/LOX creates uncertainty, drug-device attribute determination. NMPA’s combination-product attribute service has a stated 20-working-day decision target excluding supplements and expert consultation.
Gate 1 · 6–12 months: China Product Technical Requirements, representative-product testing, translation/localization and QMS dossier. Planning range: €0.2m–€0.8m.
Gate 2 · 6–24 months: clinical evaluation; a China clinical trial is required only if literature/equivalence and other evidence are insufficient. Planning range: €0.5m–€4m, depending on trial requirement.
Gate 3: Class III technical review has a statutory 90-working-day review period, with additional time for deficiency responses and the administrative decision. Practical submission-to-decision planning: 6–12 months.
Clinical-outcome claims, a substantially new ventilation architecture, automatic closed-loop temperature control, integrated monitoring modules, reusable patient-contact components, sterile single-use disposables, an integrated liquid-oxygen reservoir, or a drug-device combination determination can each add dedicated verification, clinical and authority-interaction gates. None of the timelines above should be read as a commitment.
Standards & evidence matrix
The standards package is a design input, not a checklist at the end.
The exact editions and harmonized / FDA-recognized / Chinese-adopted status must be frozen at each submission date. The matrix below shows the core standards expected for the present AIRCHILL minimum certifiable configuration (MCC) and conditional standards triggered by design choices, including any purchased/OEM modules incorporated into the final system. It is deliberately broader than a single-market test list.
EU/DE: QMS basis for MDR conformity assessment. FDA: incorporated into QMSR / 21 CFR Part 820 since 2 Feb 2026. China: quality-system dossier and inspection expectations mapped to NMPA requirements.Core · all markets
Hazard analysis spanning ventilation failure, hypothermia/overcooling, condensation, oxygen enrichment, fire, cryogenic injury, software, transport, alarm and use risks. Risk controls must trace into verification and labeling.Core
Basic safety and essential performance; 60601-1-2 EMC; 60601-1-8 alarms; 60601-1-12 emergency-medical-services environment. If automated physiologic feedback directly controls cooling, 60601-1-10 closed-loop-controller requirements become a specific review point.Core + conditional
Particular basic-safety and essential-performance standard for ventilators in the EMS environment. FDA recognizes the 2023 edition; China has adopted YY 9706.284-2023, effective 1 May 2026. If a future claim expands to critical-care use, ISO 80601-2-12 / the corresponding national adoption must also be assessed.MCC particular standard
Part 1 risk process plus particulate matter, volatile organic compounds and condensate/leachables. Particularly important because AIRCHILL deliberately changes gas temperature and may create condensation. China uses the YY/T 1778 series as the local adoption framework.Core gas-path evidence
Materials, ignition risk, cleaning and design for oxygen-rich gas paths. This becomes more critical if high-FiO2 operation, oxygen mixing, pressure regulation or LOX storage/vaporization is integrated.Core for O2 path
Software life-cycle processes and health-software cybersecurity where software controls ventilation, cooling, alarms, logging, connectivity or updates. FDA additionally requires its current cybersecurity premarket documentation where a cyber device is involved.If software / connectivity
Critical tasks include ventilation setup, gas-source connection, target-temperature selection, alarm response, switching between transport and hospital power/gas, emergency bypass and stopping cooling.Core
For direct or indirect patient-contact materials not fully addressed by the breathing-gas-path framework. Biological-evaluation plan should justify which endpoints are required rather than automatically testing the entire series.As applicable
GCP framework for device clinical investigations; in Europe combined with MDR Articles 62–82 / Annex XV and MPDG requirements in Germany; in the U.S. combined with IDE, IRB and informed-consent requirements; in China with NMPA device-GCP requirements.Clinical gate
Information supplied by the manufacturer, symbols, warnings, contraindications, gas-source requirements, storage/transport limits, cleaning, servicing and residual-risk communication.Labeling / IFU
Assess for standardized patient and circuit interfaces. If humidification is integrated, ISO 80601-2-74 becomes relevant; if gas monitoring is integrated, the corresponding ISO 80601 particular standards apply.Architecture dependent
ISO 17664 for reprocessing information; ISO 11607 for sterile-barrier packaging; ISO 11135 / 11137 / 17665 depending on EO, radiation or moist-heat sterilization. These are triggered by the final reusable / sterile-single-use architecture.Disposable / reusable dependent
MDR 2017/745 GSPR and Annex II/III technical documentation, clinical evaluation / PMCF under Annex XIV, PMS/PSUR, vigilance, UDI and EUDAMED obligations. Germany adds MPDG and, for routine operation after market entry, MPBetreibV requirements.EU / Germany
GB 9706.1-2020 plus applicable YY 9706 collateral and particular standards; YY 9706.284-2023 is the key EMS-ventilator particular standard. Product Technical Requirements must identify the Chinese mandatory and applicable recommended standards used for registration testing.NMPA
This is a core/applicability matrix, not a declaration that every listed standard applies to the final product. Final applicability depends on intended use, final architecture, accessories, gas source, reusable/sterile design, software functions and market-specific recognized/harmonized editions at the time of submission.
Medical oxygen / liquid oxygen
Using medical oxygen does not automatically turn AIRCHILL into a medicinal product — integrating it could.
Medical oxygen is a medicinal product. The regulatory consequence depends on what is placed on the market together, what AIRCHILL does to the oxygen stream, and whether the medicinal action or the device action is principal. This question should be closed before design freeze because an integrated LOX architecture can change classification, evidence, manufacturing controls and market-access time.
Device that administers a separately supplied medicine
If AIRCHILL connects to an independently supplied, authorized medical-oxygen source and does not place the medicinal product on the market as an integral constituent, the device can remain regulated as a medical device intended to administer a medicinal product. In the EU, MDR Article 1(9) keeps such administration devices under the MDR. Rule 12 classifies active administration devices as IIa unless administration is potentially hazardous; for a life-support ventilator in an emergency setting, the existing IIb planning hypothesis remains the conservative position. The mere use of oxygen does not by itself trigger Rule 14.
Planning impact: approximately 0–6 additional months / €0.1m–€0.5m for oxygen compatibility, dosing/mixing validation, labeling and regulatory clarification, not a new drug-development programme.
Still potentially a device — but the administration function becomes central
Changing flow, FiO2, pressure, humidity or temperature does not automatically create a new medicinal product. It does, however, make the device responsible for the accuracy, stability and safety of the delivered medicinal-gas dose and physical condition. The technical file must therefore prove concentration/flow accuracy, gas temperature, condensate control, oxygen compatibility, alarm limits and safe failure modes. If the conditioning were to alter pharmaceutical quality or create a product intended only for one specific medicinal-oxygen presentation, competent-authority consultation becomes more important.
Planning impact: normally inside the device V&V programme; reserve €0.2m–€0.8m for the additional gas-path and oxygen-specific verification package.
Potential Class III / drug-device consultation route in Europe
If a medicinal substance is incorporated as an integral part of the device and its action is ancillary to the device, MDR Article 1(8) applies and Rule 14 classifies the device as Class III. The Notified Body must assess the device and consult a competent medicinal-products authority on the quality, safety and benefit/risk of the medicinal substance. If the medicinal action is instead the principal mode of action, the integrated product moves into medicinal-product legislation, with the relevant MDR GSPR still applying to the device part.
An onboard LOX vessel also creates a separate engineering-regulatory layer: cryogenic storage, pressure relief, oxygen compatibility, fire risk, transport and dangerous-goods requirements. Depending on architecture, PED / TPED and ADR analysis may be required in addition to MDR.
Planning reserve: +12–30 months and roughly €1.5m–€6m compared with an external-oxygen device case, as a risk reserve rather than an authority quote.
Worst-case pharmaceutical pathway
If the product’s principal intended action is pharmacological and the device is primarily a delivery component, the regulatory centre of gravity can move to medicinal-product law. In the EU, that can mean a medicinal-product marketing authorization with device conformity evidence / Notified-Body opinion as applicable. This is not the current AIRCHILL planning case.
Risk reserve: a genuine additional pharmaceutical development programme can add 2–5+ years and €10m–€30m+. Those figures are broad programme-planning sensitivities, not statutory fees.
Medical oxygen is a drug / designated medical gas, while ventilators and oxygen-delivery hardware are devices. A ventilator that merely administers separately supplied medical oxygen is not automatically a combination product. If AIRCHILL incorporates LOX/oxygen as a constituent, is co-packaged with a specific drug presentation, or is intended exclusively for use with a specified medicinal product, jurisdiction should be discussed with FDA’s Office of Combination Products. A Pre-RFD / RFD or combination-product meeting can resolve CDRH-versus-CDER lead-centre questions before the pivotal programme is fixed.
NMPA provides a formal drug-device combination product attribute determination service when the regulatory attribute is uncertain. The applicant must justify the product’s primary mode of action, constituent functions, intended use and regulatory status of comparable products. The published service target is 20 working days after acceptance, excluding supplementary information and expert discussion. AIRCHILL should use this route before relying on an imported-Class-III device-only plan if LOX or medicinal oxygen becomes an integral constituent.
For the first regulatory programme, the lowest-regulatory-complexity architecture is to keep authorized medical oxygen external and separately supplied, with AIRCHILL functioning as the reusable ventilator / cooling device that meters and conditions the breathing gas. An integrated LOX reservoir should be treated as a separate architecture decision with an explicit MDR Article 1(8)/(9), Rule 12/14, FDA OCP and NMPA drug-device attribute review before engineering is locked.
EU legal basis: MDR 2017/745 Article 1(8) and 1(9), Annex VIII Rule 12 and Rule 14; MDCG 2022-5 rev.1 on the borderline between medical devices and medicinal products; EMA guidance for medicinal products used with medical devices. U.S.: FDA Office of Combination Products RFD / Pre-RFD process and medical-gas/device frameworks. China: NMPA 2021 drug-device combination-product rules and the national attribute-determination service. All classifications remain hypotheses until confirmed for the final product and intended use.
Therapeutic gas module · regulatory planning
A neuroprotective or vasodilatory gas is not just another ventilator setting.
Once a gas is intentionally administered for a pharmacological neuroprotective, anti-ischaemic or vasodilatory effect, AIRCHILL moves into a much more complex drug-device development space. The cleanest first research architecture is therefore external separately supplied medical oxygen + external separately qualified investigational therapeutic gas + a gas-specific AIRCHILL research module. The gas programme remains outside the current AIRCHILL product claim.
MDR device + medicinal-product interface
A device administering a separately supplied medicinal gas may remain under MDR Article 1(9). If a medicinal substance becomes an integral constituent with ancillary action, Article 1(8) and Rule 14 can trigger a Class III consultation route. If the medicinal action becomes the principal mode of action, medicinal-product legislation becomes the lead framework. Clinical research may therefore require coordinated MDR/MPDG and investigational-medicinal-product planning with the competent authority and ethics system.
CDRH + CDER + Office of Combination Products
The device pathway and the therapeutic-gas pathway must be resolved together. An early FDA Pre-Sub should be paired, where needed, with a Pre-RFD / RFD to clarify primary mode of action and lead-center jurisdiction. A new neuroprotective indication for H₂, Ar, Xe or another gas cannot be treated as automatically covered by an existing device clearance or by designated-medical-gas status.
NMPA drug-device attribute determination
If a therapeutic gas becomes an integral or specifically coupled component, AIRCHILL should obtain formal drug-device combination-product attribute determination before relying on a device-only Class III registration plan. CMDE/CDE responsibilities then depend on the determined primary mode of action and final configuration.
12–24 months · €1–3m research-module V&V
Management sensitivity to reach a validated research prototype: gas mixing and concentration verification, hydrogen/oxygen ignition-risk engineering, leak detection, cold-circuit verification, alarms and fail-safe return to standard ventilation. This excludes the later clinical drug programme.
9–18 months · €0.5–2m+
High gas fractions primarily drive supply, cylinder weight, flow-calibration and FiO₂-control work. Argon remains the stronger neuroprotection candidate; helium is presently a thermal/flow research candidate.
12–30 months · €1–6m
Xenon adds closed-loop/recovery, end-tidal monitoring and gas-economy requirements. NO adds dedicated NO/NO₂ analyzers, reaction-time validation and methemoglobin safety controls. These are separate gas-specific architectures, not one interchangeable module.
These are 2026 management sensitivities, not authority fees or financing commitments. EU/Germany: approximately 2.5–4 years and €8–20m to a focused clinical proof-of-concept, with 5–8 years and €20–70m+ to a defensible neurological outcome claim. United States: approximately 2.5–4 years / €10–25m to PoC and 5–8 years / €25–80m+ to outcome claim. China: approximately 3–5 years / €8–25m to PoC and 5–8+ years / €20–70m+ to outcome claim. A large multinational mortality/mRS pivotal trial could exceed these ranges substantially.
Additional gas standards & controls
1. H₂: active research priority because randomized post-arrest human exposure at 2% already exists, while acknowledging the negative primary HYBRID II endpoint. 2. Argon: bench-ready platform work, clinical investment after the ongoing translational signal matures. 3. NO: separate vascular/reperfusion programme. 4. Xenon: strategic watch because of human MRI signal but major gas-recovery complexity. 5. Helium: thermal-carrier research only. CO, N₂O and H₂S are not part of the current clinical development plan.
Regulatory basis: MDR 2017/745 Articles 1(8)/(9) and Annex VIII Rules 12/14; EMA medicinal-product/device interface guidance; FDA Office of Combination Products RFD process; NMPA drug-device combination-product attribute determination. Standards and cost/timeline ranges are applicability and management-planning hypotheses until the final gas, architecture, intended purpose and study design are frozen.
Cold-air dose · regulatory evidence strategy
The lower temperature limit should be a verified design output, not a marketing number.
Human studies show that brief exposures as cold as approximately −35 to −40 °C have been experimentally delivered, while longer or high-ventilation exposures at −15 to −23 °C can produce bronchoconstriction, inflammatory or epithelial-stress signals. There is no validated universal minimum safe inspired-air temperature. For AIRCHILL, the regulator-relevant question is therefore the worst-case delivered respiratory dose: patient-side gas temperature, absolute humidity, flow/minute ventilation, pressure, duration, route and patient susceptibility.
−20 °C lower first-generation setpoint
This is a management / development assumption because product-specific prolonged endotracheal porcine evidence exists around −20 °C. It is not a biological injury threshold and is not yet a cleared or certified specification.
−25 °C and below reopen preclinical dose finding
Before expanding the claimed operating envelope, repeat prolonged route-specific work with airway histology, epithelial/inflammatory markers, mucociliary/ciliary function, secretion handling, gas exchange, mechanics and haemodynamics.
−30 to −40 °C is not a clinical target today
Published short human exposures demonstrate that these temperatures can be inhaled briefly under research conditions. They do not establish prolonged lower-airway safety and should not be used as an AIRCHILL operating claim.
Turn cold-air hazards into traceable risk controls
Hazards include bronchospasm, airway drying, secretion thickening/retention, epithelial injury, mucociliary impairment, condensation/ice/occlusion, pressure/resistance change, gas-exchange disturbance, excessive cooling and possible cardiovascular responses. Each control should trace to bench, preclinical or clinical verification.
External literature supports the rationale, not equivalence
The 39-study cold-air challenge literature and extreme-exposure physiology studies can characterize known hazards and support study design. They do not establish equivalence to prolonged endotracheal AIRCHILL delivery. Product-specific clinical data remain necessary for the intended performance/safety claim.
Ask FDA to agree the temperature-escalation package early
Present the −20 °C preclinical anchor, the external human exposure envelope, the proposed −10 → −15 → −20 °C human escalation and stopping rules. Specifically ask whether the selected first-in-human population, mucociliary/epithelial endpoints and duration support the proposed labeling limit.
One dose-qualification core
Use the same patient-side temperature/humidity/flow/duration characterization and route-specific safety package as the common evidence core, then map it into local clinical-evaluation and testing requirements.
Bench: qualify patient-side temperature, humidity, flow, condensation and essential ventilation performance across worst cases. Preclinical: confirm −20 °C and dose-find −25 °C only if needed. First human safety/performance: sequential −10/−15/−20 °C cohorts with independent safety review and airway + cardiovascular endpoints. First emergency cohort: use a previously qualified setting rather than continuing temperature escalation. Later optimization: select the dose that produces the required thermal effect with the lowest airway burden. A claim such as “safe to −20 °C for X minutes under Y ventilation/humidity conditions” should only be written after those exact conditions are prospectively supported.
Cold-Air Inhalation Safety Evidence · Research decision register · Clinical dose-escalation layout. Evidence status: external human studies = SOURCED/TRANSFERRED by route; −20 °C clinical lower-setpoint = ASSUMPTION pending product-specific human validation.
Claim ladder
Each claim earns its own evidence.
A performance-and-safety claim requires materially less evidence than a neurological outcome claim. Choosing the narrow claim first is what makes the programme financeable.
Define it narrowly
Population, setting, operators, duration and therapeutic purpose drive classification and the evidence requirement. This is decided first, not last.
Performance and safety
A temperature-performance claim supported by airway-safety evidence is the lower-risk route to market and the one currently planned.
Neurological outcome
Any survival or neurological-benefit claim requires a separate, substantially larger programme. It is not part of the current financing case.
Under the MDR, 63 % of manufacturers surveyed in the pneumology, anaesthesia and intensive care segment reported withdrawing products from the market (DIHK, MedicalMountains and SPECTARIS 2023, n = 393). We treat that as a planning parameter, not as background noise.
Reimbursement
The ambulance service is paid. The new device usually is not paid separately.
In Germany, § 133 SGB V provides the federal remuneration framework where state or municipal law does not itself set charges. The practical device question is local: who is the responsible rescue-service body, who buys the equipment, and how are readiness, transport and equipment costs reflected in the local fee or contract? Across the markets reviewed, the research does not establish a routine stand-alone AIRCHILL price per use. The early routes are procurement, fleet equipment, existing service budgets, evidence pilots or institution-specific agreements.
Regular procurement
Value has to be demonstrated to clinical, operational and purchasing stakeholders inside existing care budgets. This is what the financial model assumes.
Health economics
Workflow, time, resource use and patient outcomes require transparent data before any purchasing argument holds.
Policy pathway
A trial-related payment under § 137e SGB V, or any other special mechanism, is treated as upside only. The dual financing recommended by the Government Commission has not been implemented.
§ 133 SGB V · Bundestag Research Services WD 9-3000-093/23: responsible bodies are districts, independent cities and special-purpose associations; only Baden-Württemberg is organised under private law · Government Commission, 9th statement, 7 September 2023, drawing on the Federal Audit Office report 2018 · Our position paper on the emergency-care reform refers to BT-Drs. 21/6808.
Current stage
Next confirmation gates: classification, approval and market access.
This page describes planning assumptions. AIRCHILL does not currently hold CE/MDR conformity, FDA clearance or approval, NMPA registration, a final market-specific classification, reimbursement coverage or authorisation for routine clinical use. The FDA and China pathways remain subject to formal authority interaction and the final intended-use and claims package.
Regulatory and health-economics expertise wanted.
We are looking for a Notified Body with a capacity commitment for class IIb, FDA respiratory-device expertise for an early Pre-Submission, and China/NMPA regulatory partners experienced with imported Class III and innovative-device classification.